 |
0 Diseases |  |
5 Trials |
|
5 Trials |  |
32 News |  |
| «12 |
- | huCART19 / Novartis
Enrollment closed, Trial completion date, Trial primary completion date: Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (clinicaltrials.gov) - Nov 18, 2019
P1, N=85, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Nov 2022 | Trial primary completion date: Oct 2019 --> Oct 2021
- | huCART19 / Novartis
Enrollment change: Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (clinicaltrials.gov) - Mar 22, 2019
P1, N=85, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Nov 2022 | Trial primary completion date: Oct 2019 --> Oct 2021 N=50 --> 85
- | huCART19 / Novartis
Enrollment open: Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) - Jan 23, 2019
P2, N=85, Recruiting, Sponsor: University of Pennsylvania
N=50 --> 85 Not yet recruiting --> Recruiting
- | huCART19 / Novartis
New P2 trial: Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) - Jan 3, 2019
P2, N=85, Not yet recruiting, Sponsor: University of Pennsylvania
- | huCART19 / Novartis, CART22 / University of Pennsylvania
Enrollment open, Combination therapy: CART22 Alone or in Combination With huCART19 for ALL (clinicaltrials.gov) - Oct 2, 2018
P1, N=18, Recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | huCART19 / Novartis, CART22 / University of Pennsylvania
New P1 trial, Combination therapy: CART22 Alone or in Combination With huCART19 for ALL (clinicaltrials.gov) - Aug 8, 2018
P1, N=18, Not yet recruiting, Sponsor: University of Pennsylvania
- || huCART19 / Novartis, MTV273 / Novartis
New P1 trial: Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2018
P1, N=32, Recruiting, Sponsor: University of Pennsylvania
- | huCART19 / Novartis
Trial completion date, Trial primary completion date: Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (clinicaltrials.gov) - Apr 24, 2018
P1, N=50, Recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Mar 2018 --> Oct 2019
- huCART19 / Novartis
Enrollment open: Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (clinicaltrials.gov) - Sep 7, 2016
P1, N=50, Recruiting, Sponsor: University of Pennsylvania
Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Mar 2018 --> Oct 2019 Active, not recruiting --> Recruiting
- huCART19 / Novartis
Enrollment closed: Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (clinicaltrials.gov) - Aug 29, 2016
P1, N=50, Active, not recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- huCART19 / Novartis
New P1 trial: Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (clinicaltrials.gov) - Feb 27, 2015
P1, N=50, Recruiting, Sponsor: University of Pennsylvania